60282-85-1

Upstream product

• 17356-08-0 thiourea 
• 90-99-3 diphenylchloromethane 
• 91-01-0 1,1-Diphenylmethanol 

Downstream Products

• 2254-91-3 3-benzhydrylsulfanyl-[1,2,4]thiadiazole 
• 27925-76-4 AB₄₇₃₇₄ 
• 4237-48-3 diphenylmethanethiol 

Relevant academic research and scientific papers

Sulfoxide-Chelated Ruthenium Benzylidene Catalyst: a Synthetic Study on the Utility of Olefin Metathesis

We provide an experimental summary of selected advances in olefin metathesis methodology that were reported over the past decades. A stable and universal sulfoxide-chelated ruthenium olefin metathesis catalyst [RuCl2(SIMes)(=CH?C6H4?S(O)Ph)], SIMes=1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidene, was introduced and its application profile was studied in detail. A range of model substrates of natural origin was developed and successfully metathesized with variants of the reaction, such as ene–yne, cross, or ring-closing metathesis. All reported reactions were performed in non-pretreated solvents and in air to demonstrate the user-friendliness of the system. Besides the great functional group tolerance exhibited by the reported complex, its compatibility with multiple solvents was determined along with its air and moisture stability. Additionally, an interesting effect increasing the reaction efficiency was observed, if reactions were performed at temperatures around the solvent boiling point.

Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus

The first step in HIV infection is the binding of the envelope glycoprotein gp120 to the host cell receptor CD4. An interfacial "Phe43 cavity" in gp120, adjacent to residue Phe43 of gp120-bound CD4, has been suggested as a potential target for therapeutic intervention. We designed a CD4 mutant (D1D2F43C) for site-specific coupling of compounds for screening against the cavity. Altogether, 81 cysteine-reactive compounds were designed, synthesized, and tested. Eight derivatives exceeded the affinity of native D1D2 for gp120. Structure-activity relationships (SAR) for derivatized CD4 binding to gp120 revealed significant plasticity of the Phe43 cavity and a narrow entrance. The primary contacts for compound recognition inside the cavity were found to be van der Waals interactions, whereas hydrophilic interactions were detected in the entrance. This first SAR on ligand binding to an interior cavity of gp120 may provide a starting point for structure-based assembly of small molecules targeting gp120-CD4 interaction.

INHIBITION OF CELL PROLIFERATION

The disclosed modulators of Rb:Raf-1 interactions are potent, selective disruptors of Rb:Raf-1 binding, with IC50 values ranging from 80 nM to 500 nM. Further, these compounds are surprisingly effective in inhibiting a wide variety of cancer cells, including osteosarcoma, epithelial lung carcinoma, non small cell lung carcinoma, three different pancreatic cancer cell lines, two different glioblastoma cell lines, metastatic breast cancer, melanoma, and prostate cancer. Moreover, the disclosed compounds effectively disrupt angiogenesis and significantly inhibited tumors in nude mice derived from human epithelial lung carcinoma tumors. Accordingly, the disclosed compounds, pharmaceutical compositions comprising the compounds, methods of inhibiting cell proliferation, methods of treating subjects with cancer, and methods of preparing the disclosed compounds are provided.

IMPROVED PROCESS FOR PREPARING BENZHYDRYLTHIOACETAMIDE

The present invention is directed to an improved process for preparing modafinil wherein benzhydrylthioacetate is prepared in high yield and purity by the reaction of a haloacetate with the reaction product of thiourea and benzhydrol. The reaction employing the haloacetate is conducted in a solvent comprising an organic solvent such as methanol having dissolved therein an organic base or an inorganic basic salt such as sodium bicarbonate. The resulting benzhydrylthioacetate can be amidated and then oxidized to provide the pharmaceutical grade modafinil in high yield and purity.

PROCESS FOR PREPARING POLYMORPHIC FORM (I) OF MODAFINIL

A process is described for preparing polymorphic form (I) of modafinil with high yields and with low impurity content. The process comprises the steps of (a) reacting (diphenylmethyl)thioacetic acid with a C1-C5 alcohol,(b) oxidation of the resulting este